KORU Medical Systems
KORU Medical Systems' revenue rose 22.2% to $41 million in fiscal 2025. Its operating margin was −7.2%, up from −19.2% a year earlier. Free cash flow was −$0 million. The diluted share count rose 0.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What KORU Medical Systems does
KORU Medical makes and sells devices that deliver drugs by infusion under the skin, called subcutaneous infusion, in large volumes. Its main product line is the FREEDOM Infusion System, which includes syringe drivers, needle sets and flow-rate tubing. The system is used mostly to give immunoglobulin therapy to people with primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy, a nerve disorder. Patients can use it at home or in infusion centers.
The company gets revenue from three sources: its domestic core business in the United States and Canada, its international core business, and pharma services and clinical trials. The core revenue is from sales of syringe drivers, tubing and needles. Pharma services revenue comes from supplying devices for clinical trials of drugs, and from engineering work to customize the system for drug makers.
It says it aims to deepen its place in subcutaneous immunoglobulin and extend into other new subcutaneous drug therapies. It was incorporated in 1980.
Its biggest risks, as it describes them
- Failing to bring out new products or keep up with changing technology.
- Its business depends on a supply of drugs, such as plasma-based immunoglobulin products, that its devices deliver.
- Changes in FDA approvals for the drugs, or new therapies that need no device, could reduce demand.
- The markets for its products may be smaller than it estimates.
Income statement
From fiscal 2016 to 2019, earnings per share fell 20.6% a year and net income 9.1% a year, as new shares raised the share count by 3% and diluted each share's earnings. KORU Medical Systems then lost money in fiscal 2020, 2021, 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 25 | 17 | 12 | 10 | 9 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −530.9x | −378.4x | −202.0x | −89.6x | −53.5x |
| Current ratio | 7.8x | 4.3x | 4.5x | 2.7x | 2.4x |
| Quick ratio | 6.5x | 3.4x | 3.8x | 2.3x | 2.0x |
Cash flow
Projections
Project KORU Medical Systems' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What KORU Medical Systems says to expect
- Full year 2026: revenue
Revising full-year 2026 revenue guidance to $48.0 - $48.5 million, representing year-over-year growth of 17% - 18%, compared to the previous guidance range of $47.5 - $48.5 million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $241,615 of KORU Medical Systems shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | Eric SchillerChief Technology Officer | Bought | 8,546 | $3.63 | $31,022 | Form 4 |
| Sep 8, 2026 | Adam R KalbermattenChief Commercial Officer | Bought | 32,000 | $3.16 | $101,120 | Form 4 |
| Jun 11, 2026 | Adam R KalbermattenPresident-Chief Commercial Off | Bought | 12,500 | $3.94 | $49,275 | Form 4 |
| May 18, 2026 | Eric SchillerChief Technology Officer | Bought | 5,000 | $3.91 | $19,550 | Form 4 |
| May 14, 2026 | Thomas Edward AdamsChief Financial Officer | Bought | 5,500 | $3.86 | $21,248 | Form 4 |
| May 14, 2026 | Christopher PazdanChief Operating Officer | Bought | 5,000 | $3.88 | $19,400 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −17.7% | 13.2% | 21.1% |
| Altman Z'' | 1.18 | −0.54 | −0.06 |
| Accruals ratio | −25.0% | −20.6% | −11.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put KORU Medical Systems side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| KORU Medical Systems | FY25 | 22.2% | −7.2% | −1.1% | — | — | — | |
| Myomo | FY25 | 25.7% | −35.2% | −39.7% | — | — | 3 | Compare |
| Pulsenmore | FY25 | 314.3% | — | −82.5% | — | — | — | Compare |
| SS Innovations International | FY25 | 105.7% | −19.3% | −52.3% | — | — | — | Compare |
| Utah Medical Products | FY25 | −5.8% | 29.6% | 37.2% | 26.8% | −6.0x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 12 | 12 | 17 | 23 | 24 | 24 | 28 | 28 | 34 | 41 |
| Revenue growth | 8.9% | 0.4% | 41.2% | 33.5% | 4.4% | −2.8% | 18.8% | 2.2% | 18.0% | 22.2% |
| Gross profit | 8 | 8 | 11 | 15 | 15 | 14 | 15 | 17 | 21 | 26 |
| Research and development | 0 | 0 | 0 | 1 | 1 | 2 | 5 | 6 | 5 | 4 |
| Operating income | 1 | −1 | 1 | 1 | −1 | −7 | −11 | −10 | −6 | −3 |
| Net income | 1 | −0 | 1 | 1 | −1 | −5 | −9 | −14 | −6 | −3 |
| Diluted EPS (US$) | 0.02 | −0.01 | 0.02 | 0.01 | −0.03 | −0.10 | −0.19 | −0.30 | −0.13 | −0.06 |
| Diluted shares (millions) | 38 | 38 | 39 | 39 | 42 | 44 | 45 | 46 | 46 | 46 |
| Cash flow | ||||||||||
| Cash from operations | 2 | −0 | 2 | 0 | −1 | −4 | −5 | −5 | −0 | 0 |
| Capital expenditure | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 1 | 1 | 1 |
| Free cash flow | 2 | −1 | 1 | 0 | −2 | −5 | −8 | −6 | −2 | −0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 1 | 2 | 3 | 3 | 3 | 3 | 3 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 4 | 3 | 4 | 6 | 27 | 25 | 17 | 12 | 10 | 9 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 8 | 8 | 10 | 14 | 40 | 41 | 42 | 28 | 27 | 28 |
| Total liabilities | 1 | 2 | 2 | 3 | 4 | 5 | 11 | 8 | 10 | 11 |
| Shareholders' equity | 7 | 7 | 9 | 11 | 36 | 36 | 31 | 20 | 17 | 17 |
| Margins and ratios | ||||||||||
| Gross margin | 62.1% | 61.6% | 62.3% | 64.1% | 61.8% | 58.6% | 55.1% | 58.6% | 63.4% | 62.3% |
| Operating margin | 9.7% | −6.0% | 6.7% | 2.5% | −5.2% | −29.9% | −38.6% | −36.0% | −19.2% | −7.2% |
| Net margin | 6.4% | −4.3% | 5.2% | 2.4% | −5.0% | −19.4% | −31.1% | −48.2% | −18.0% | −6.4% |
| Free cash flow margin | 14.6% | −4.3% | 6.8% | 0.5% | −6.9% | −19.9% | −29.3% | −19.9% | −4.8% | −1.1% |
| Rule of 40 (growth + FCF margin) | 23.6% | −4.0% | 48.0% | 34.0% | −2.5% | −22.7% | −10.5% | −17.7% | 13.2% | 21.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 11.7% | −7.8% | 11.7% | 5.6% | −5.1% | −12.6% | −25.5% | −53.2% | −32.6% | −15.6% |
| Return on assets | 10.0% | −6.5% | 9.7% | 4.6% | −4.5% | −11.2% | −20.7% | −38.8% | −21.8% | −9.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |